Novartis is scheduled to report Q2 2026 results with a consensus revenue estimate of $14.50 billion and an EPS of $2.20, while the stock currently trades at $154.31 against an average price target of $144.00. Investors are laser-focused on the severity of generic erosion for the blockbuster heart-failure drug Entresto following its recent patent expiration in the U.S. and Europe.
This patent cliff is expected to be partially mitigated by the continued double-digit growth of newer oncology and immunology therapies like Kisqali and Pluvicto. Analysts are looking for confirmation that these priority brands can stabilize margins as the company completes its transition into a pure-play innovative medicines firm.